GLP-1 receptor agonists × adverse events & safety

TrialInternational journal of obesity (2005)2014

Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.

M E J Lean et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 564 people · 2014

Randomised comparison

Probably raised adverse events & safety

+2.90kg+0.50 to +5.30

As reported

difference 2.9 kg, 95% CI 0.50–5.30

One number in the abstract

the abstract, start to end

with none (a treatment difference of 2.9 kg (95% confidence interval

← favours treatmentfavours comparator →
could be chance
Adverse events & safety
2.90.50–5.30
GLP-1 receptor agonistsAdverse events & safety

GLP-1 receptor agonists × adverse events & safetyharms?mixed

unlikelylikely
0.020.00 without it
← favours treatmentfavours comparator →
more certainless certain
1 / 5

78 papers cite itlatest 60 shown

2014
2015
2016
2017
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 23942319